For all orthopaedic conditions, we suggest that patients consult their primary physician, rheumatologist, or orthopaedic surgeon for conservative treatment options for pain and dysfunction.
When relief of pain and dysfunction is not achieved, until recently, a patient needed to either accept it or consider surgical treatment. Our physicians perform orthopaedic operations on an ongoing basis in their practices. While they are very successful procedures, they do have risks and limitations.
Now patients and referring physicians have a new option:
Stem cell treatment offers the potential for millions of viable mesenchymal stem cells to differentiate into normal healing tissues and can be injected into painful joints, around painful tendons and ligaments and given as an IV for systemic use.
We encourage patients to seek standard conservative care through their physicians before considering stem cell treatment, but should consider it before major surgeries. In many, if not most cases, surgery may still be the best option.
If you are unsure, our physicians are highly qualified to review your case and advise you. They are musculoskeletal experts and treat these problems on a ongoing basis.
- Dr. David is a Fellowship Trained Sports Medicine and Arthroscopy specialist
- Dr. Hanson is a Fellowship Trained Hip and Knee Joint Replacement specialist
- Dr. Salt is a Fellowship Trained Plastic Surgeon
- Dr. Olsen is Board-Certified in Preventative Medicine
- Patrick Astourian, MS, PA-C has years of experience as an orthopaedic PA
At the San Diego Stem Cell Treatment Center, we require patients to be thoroughly evaluated in order to avoid unnecessary treatment with this technology.
If you choose to have treatment through SDSCTC, you will be asked to sign a consent to follow you prospectively to evaluate the effectiveness of your care. We will be combining our data with that of all the other affiliates of the Cell Surgical Network around the United States. This will allow us to determine the ability of this technology to treat these orthopaedic maladies going forward. We look forward to a future where we can accurately predict the efficacy of SVF Deployments.